Charles River Laboratories International, Inc.
CRL · NYSE
6/28/2025 | 3/29/2025 | 12/31/2024 | 9/28/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.69 | 0.03 | -1.58 |
| FCF Yield | 2.30% | 1.43% | 0.89% | 2.09% |
| EV / EBITDA | 45.16 | 57.75 | -138.45 | 60.75 |
| Quality | ||||
| ROIC | 1.14% | 0.82% | -2.53% | 1.29% |
| Gross Margin | 34.59% | 32.28% | 28.35% | 34.56% |
| Cash Conversion Ratio | 3.85 | 3.88 | 6.63 | -0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.54% | -1.21% | -0.56% | 0.62% |
| Free Cash Flow Growth | 50.66% | 34.18% | -60.70% | 38.31% |
| Safety | ||||
| Net Debt / EBITDA | 11.79 | 14.96 | -29.26 | 12.16 |
| Interest Coverage | 3.34 | 2.68 | -5.94 | 3.88 |
| Efficiency | ||||
| Inventory Turnover | 2.41 | 2.30 | 2.58 | 1.97 |
| Cash Conversion Cycle | 84.76 | 88.21 | 82.03 | 94.50 |